Table 1.
IgY technologies show advantages compared to antibodies from mammals.
| Area of Advantage | IgY Advantage | Reference |
|---|---|---|
| Animal care | Replaces the bleeding of the animals by the collection of eggs, promoting animal welfare and reducing suffering associated with painful handling | [16,17,18,19] |
| Biotechnology, diagnosis, and human treatment |
Low-cost production | [13,14,15,16,17,18,19,20,21,22,23,24,55,56] |
| Antibodies against mammal conserved proteins | ||
| High-yield of production | ||
| High specificity | ||
| Can be used as polyclonal, monoclonal, Fab, or scFv | ||
| IgY Fc does not interact with Fc receptors | ||
| IgY Fc does not activate complement | ||
| Human treatment | Toxic side-effects not yet reported; if used in pure form they can even be used in patients with allergy to eggs | [55,56] |
| Passive immunization technology is applicable in newborns and adults, in immunodeficient patients and in pregnant women |